da David Jiang, MD
Urology · Portland, ORNPI 1639556384
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (55.8%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 90.8% of it on its own, with 22 other manufacturers making up the rest. 2025 is the largest year on record at $38,799, more than ten times the $870 reported in 2019. Among urology clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 198 payments — averaging $327.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$59K
- Angiodynamics, Inc.$2K
- Procept Biorobotics Corporation$1K
- Coloplast$526
- Sumitomo Pharma America, Inc.$411
- Astellas Pharma US Inc$326
- plus $1K from 17 others
What the payments were for
- Speaking & faculty fees$8,50013%
- Travel & lodging$12,94620%
- Food & beverage$7,23211%
- Education$36,15156%
- Gifts$90%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 100 | $58,898 |
| Angiodynamics, Inc. | 11 | $2,249 |
| Procept Biorobotics Corporation | 10 | $1,155 |
| Coloplast | 9 | $526 |
| Sumitomo Pharma America, Inc. | 7 | $411 |
| Astellas Pharma US Inc | 13 | $326 |
| AbbVie | 12 | $261 |
| Tolmar, Inc. | 9 | $204 |
| Profound Medical Corp. | 2 | $171 |
| Boston Scientific | 4 | $170 |
| Pfizer | 5 | $113 |
| Progenics Pharmaceuticals, Inc. | 3 | $81 |
| Teleflex LLC | 1 | $64 |
| AstraZeneca | 1 | $35 |
| Laborie Medical Technologies Corp. | 2 | $26 |
| Sun Pharmaceutical Industries Inc. | 1 | $25 |
| Ferring Pharmaceuticals Inc. | 1 | $23 |
| Olympus America Inc. | 1 | $22 |
| Accord Healthcare, Inc. | 1 | $22 |
| Baxter Healthcare | 1 | $18 |
| Urovant Sciences Inc | 1 | $16 |
| Endo Pharmaceuticals Inc. | 1 | $13 |
| Travere Therapeutics, Inc. | 2 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$56,555
- Nanoknife$2,160
- DA VINCI SP$1,000
- AquaBeam Robotic System$888
- TITAN$360
- rezum Generator$128
- GEMTESA$114
How this compares
$64,837 in reported general payments places this provider in the 95th percentile of 153 urology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 78 | $63,407 |
| GemtesaVibegron | 42 | $26,162 |
| Tamsulosin Hcl | 339 | $4,841 |
| Finasteride | 290 | $3,131 |
| Tadalafil | 128 | $2,472 |
| Testosterone Cypionate | 38 | $2,411 |
| Potassium Citrate ErPotassium Citrate | 21 | $2,399 |
| Estradiol | 38 | $1,941 |
| Methenamine Hippurate | 13 | $1,056 |
| Dutasteride | 36 | $982 |
| Cephalexin | 50 | $938 |
| Trospium Chloride | 15 | $829 |
| Tolterodine Tartrate ErTolterodine Tartrate | 20 | $769 |
| Desmopressin Acetate | 21 | $629 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 14 | $424 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $326 | $63,40778 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $411 | $26,16242 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 153 urology providers in Oregon.
Other urology in Portland
- Lance MarrPortland$323K
- Amir PatelPortland$36K
- James TycastPortland$35K
- Sudhir IsharwalPortland$30K
- Ian MetzlerPortland$23K
- Sara Spettel AliyarPortland$21K
- Daniel JanoffPortland$15K
- James BreseePortland$14K
- Stanley MyersPortland$11K
- Sajal DuttaPortland$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.